<p><strong>Liquidia Corporation</strong>（纳斯达克代码：LQDA）在经历了一段动荡时期后，最近一个月的表现非常出色，股价上涨了 30%。上个月的涨幅为过去一年内 213% 的大幅增长画上了句号。</p>
<p>在如此大幅的价格跳升之后，Liquidia 的市销率（或称&#34;P/S&#34;）为 43.2 倍，这使得与美国制药行业的其他公司相比，它看起来像是一个强烈的卖出信号，而在该行业中，大约一半的公司市销率低于 4 倍，甚至市销率低于 1.3 倍的情况也相当普遍。不过，仅仅根据市销率的表面值来判断并不明智，因为可能有解释其如此高的原因。</p>
<p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
<p>查看我们对 Liquidia 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/22761611-ps-multiple-vs-industry-1-dark-2/1765031919896?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/22761611-ps-multiple-vs-industry-1-dark-2/1765031919896"/></p>
<p>纳斯达克 CM:LQDA 市销率与行业对比 2025 年 12 月 6 日</p>
<h3>Liquidia 最近的表现如何？</h3>
<p>最近一段时间对 Liquidia 来说是有利的，因为其收入增长速度超过了大多数其他公司。似乎许多人预计强劲的收入表现将持续下去，这提高了市销率。然而，如果情况并非如此，投资者可能会因支付过高的股价而受到影响。</p>
<p>如果您想了解分析师对未来的预测，您应该查看我们关于 Liquidia 的 <strong>免费</strong> 报告。</p>
<h2>Liquidia 的收入增长趋势如何？</h2>
<p>您真正能够安心看到 Liquidia 如此高的市销率的唯一时机是当公司的增长显著超越行业时。</p>
<p>回顾过去，我们看到公司在过去 12 个月的收入经历了快速增长。最近三年期间，收入也经历了令人难以置信的整体增长，这得益于其出色的短期表现。因此，可以公平地说，最近的收入增长对公司来说是极好的。</p>
<p>展望未来，预计未来三年将每年产生 118% 的增长，这是由八位关注该公司的分析师估算的。与行业每年仅预测增长 30% 相比，该公司有望实现更强的收入结果。</p>
<p>鉴于此，Liquidia 的市销率高于大多数其他公司是可以理解的。似乎大多数投资者都在期待这种强劲的未来增长，并愿意为该股票支付更高的价格。</p>
<h2>我们可以从 Liquidia 的市销率中学到什么？</h2>
<p>强劲的股价飙升导致 Liquidia 的市销率也随之飙升。我们认为市销率的作用主要不是作为估值工具，而是用来衡量当前投资者情绪和未来预期。</p>
<p>我们已经确定 Liquidia 维持其高市销率的原因在于其预测的收入增长高于制药行业的其他公司，正如预期的那样。看来，股东对公司的未来收入充满信心，这支撑了市销率。除非分析师们真的大错特错，否则这些强劲的收入预测应该会保持股价的稳定。</p>
<p>在您采取下一步之前，您应该了解我们发现的 <strong>Liquidia 的一个警示信号</strong>。</p>
<p><strong>如果您对过去盈利增长稳健的公司感兴趣</strong>，您可能希望查看这份 <strong>免费</strong> 的其他强劲盈利增长和低市盈率公司的集合。</p>

LQDA

<p>Liquidia Corporation（纳斯达克代码：LQDA）的股价最近上涨了 30%，使其在过去一年中累计增长了 213%。尽管其市销率高达 43.2 倍，但由于强劲的收入增长预测，投资者仍然持乐观态度，预计未来三年年增长率将达到 118%，而行业平均为 30%。高市销率反映了投资者的情绪和未来预期，但由于潜在风险，仍需保持谨慎</p>

<p><strong>Liquidia Corporation</strong> (NASDAQ:LQDA) shares have had a really impressive month, gaining 30% after a shaky period beforehand. The last month tops off a massive increase of 213% in the last year.</p>
<div class="lb-trans"><p><strong>Liquidia Corporation</strong>（纳斯达克代码：LQDA）在经历了一段动荡时期后，最近一个月的表现非常出色，股价上涨了 30%。上个月的涨幅为过去一年内 213% 的大幅增长画上了句号。</p>
</div><p>After such a large jump in price, Liquidia's price-to-sales (or &#34;P/S&#34;) ratio of 43.2x might make it look like a strong sell right now compared to other companies in the Pharmaceuticals industry in the United States, where around half of the companies have P/S ratios below 4x and even P/S below 1.3x are quite common. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so lofty.</p>
<div class="lb-trans"><p>在如此大幅的价格跳升之后，Liquidia 的市销率（或称&#34;P/S&#34;）为 43.2 倍，这使得与美国制药行业的其他公司相比，它看起来像是一个强烈的卖出信号，而在该行业中，大约一半的公司市销率低于 4 倍，甚至市销率低于 1.3 倍的情况也相当普遍。不过，仅仅根据市销率的表面值来判断并不明智，因为可能有解释其如此高的原因。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
</div><p>See our latest analysis for Liquidia</p>
<div class="lb-trans"><p>查看我们对 Liquidia 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/22761611-ps-multiple-vs-industry-1-dark-2/1765031919896" alt="" original-src="https://images.simplywall.st/asset/chart/22761611-ps-multiple-vs-industry-1-dark-2/1765031919896"/></p>
<p>NasdaqCM:LQDA Price to Sales Ratio vs Industry December 6th 2025</p>
<div class="lb-trans"><p>纳斯达克 CM:LQDA 市销率与行业对比 2025 年 12 月 6 日</p>
</div><h3>What Does Liquidia's Recent Performance Look Like?</h3>
<div class="lb-trans"><h3>Liquidia 最近的表现如何？</h3>
</div><p>Recent times have been advantageous for Liquidia as its revenues have been rising faster than most other companies. It seems that many are expecting the strong revenue performance to persist, which has raised the P/S. However, if this isn't the case, investors might get caught out paying too much for the stock.</p>
<div class="lb-trans"><p>最近一段时间对 Liquidia 来说是有利的，因为其收入增长速度超过了大多数其他公司。似乎许多人预计强劲的收入表现将持续下去，这提高了市销率。然而，如果情况并非如此，投资者可能会因支付过高的股价而受到影响。</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on Liquidia.</p>
<div class="lb-trans"><p>如果您想了解分析师对未来的预测，您应该查看我们关于 Liquidia 的 <strong>免费</strong> 报告。</p>
</div><h2>How Is Liquidia's Revenue Growth Trending?</h2>
<div class="lb-trans"><h2>Liquidia 的收入增长趋势如何？</h2>
</div><p>The only time you'd be truly comfortable seeing a P/S as steep as Liquidia's is when the company's growth is on track to outshine the industry decidedly.</p>
<div class="lb-trans"><p>您真正能够安心看到 Liquidia 如此高的市销率的唯一时机是当公司的增长显著超越行业时。</p>
</div><p>Taking a look back first, we see that the company's revenues underwent some rampant growth over the last 12 months. The latest three year period has also seen an incredible overall rise in revenue, aided by its incredible short-term performance. Therefore, it's fair to say the revenue growth recently has been superb for the company.</p>
<div class="lb-trans"><p>回顾过去，我们看到公司在过去 12 个月的收入经历了快速增长。最近三年期间，收入也经历了令人难以置信的整体增长，这得益于其出色的短期表现。因此，可以公平地说，最近的收入增长对公司来说是极好的。</p>
</div><p>Turning to the outlook, the next three years should generate growth of 118% each year as estimated by the eight analysts watching the company. With the industry only predicted to deliver 30% per year, the company is positioned for a stronger revenue result.</p>
<div class="lb-trans"><p>展望未来，预计未来三年将每年产生 118% 的增长，这是由八位关注该公司的分析师估算的。与行业每年仅预测增长 30% 相比，该公司有望实现更强的收入结果。</p>
</div><p>In light of this, it's understandable that Liquidia's P/S sits above the majority of other companies. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.</p>
<div class="lb-trans"><p>鉴于此，Liquidia 的市销率高于大多数其他公司是可以理解的。似乎大多数投资者都在期待这种强劲的未来增长，并愿意为该股票支付更高的价格。</p>
</div><h2>What We Can Learn From Liquidia's P/S?</h2>
<div class="lb-trans"><h2>我们可以从 Liquidia 的市销率中学到什么？</h2>
</div><p>The strong share price surge has lead to Liquidia's P/S soaring as well. We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.</p>
<div class="lb-trans"><p>强劲的股价飙升导致 Liquidia 的市销率也随之飙升。我们认为市销率的作用主要不是作为估值工具，而是用来衡量当前投资者情绪和未来预期。</p>
</div><p>We've established that Liquidia maintains its high P/S on the strength of its forecasted revenue growth being higher than the the rest of the Pharmaceuticals industry, as expected. It appears that shareholders are confident in the company's future revenues, which is propping up the P/S. Unless the analysts have really missed the mark, these strong revenue forecasts should keep the share price buoyant.</p>
<div class="lb-trans"><p>我们已经确定 Liquidia 维持其高市销率的原因在于其预测的收入增长高于制药行业的其他公司，正如预期的那样。看来，股东对公司的未来收入充满信心，这支撑了市销率。除非分析师们真的大错特错，否则这些强劲的收入预测应该会保持股价的稳定。</p>
</div><p>Before you take the next step, you should know about the <strong>1 warning sign for Liquidia</strong> that we have uncovered.</p>
<div class="lb-trans"><p>在您采取下一步之前，您应该了解我们发现的 <strong>Liquidia 的一个警示信号</strong>。</p>
</div><p><strong>If companies with solid past earnings growth is up your alley</strong>, you may wish to see this <strong>free</strong> collection of other companies with strong earnings growth and low P/E ratios.</p>
<div class="lb-trans"><p><strong>如果您对过去盈利增长稳健的公司感兴趣</strong>，您可能希望查看这份 <strong>免费</strong> 的其他强劲盈利增长和低市盈率公司的集合。</p>
</div>

Liquidia Corporation（NASDAQ:LQDA）股价上涨 30%，表现得恰到好处